Drug · DIN 02027887
PAXIL TAB 10MG
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since March 31, 2025; first marketed January 31, 1997.
- Drug Identification Number (DIN)
- 02027887
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Paroxetine N06AB05
- Class
- Human
- Record last updated
- May 1, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PAROXETINE (PAROXETINE HYDROCHLORIDE) | 10 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- June 22, 2001: NOC 2519New Drug Submission (NDS) · Change in manufacturer name
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “paxil”. A notice may cover another product or only some lots: read it to see what it covers.
- Recall of Paxil Products (2014-04-08)May 1, 2014 · Drugs · Product safety · Type III
- Important safety information on Paxil (paroxetine) and increased risk of cardiac defects following exposure during first trimester of pregnancy - For Health Professionals - GlaxoSmithKline Inc.December 16, 2005 · Drugs
- Archived - Paxil (paroxetine) and Possible Increased Risk of Birth DefectsOctober 7, 2005 · Drugs
- Important Safety Information on Paxil (paroxetine) and Possible Increased Risk of Birth Defects- For Health Professionals- GlaxoSmithKline Inc.September 29, 2005 · Drugs
- Archived - Concomitant Use of Paxil (paroxetine hydrochloride) or Paxil CR (paroxetine hydrochloride controlled release tablets) and pimozide (Orap) Resulting in Arrhythmias (Irregular Heartbeats)July 28, 2005 · Drugs
- Archived - Important Drug Warning - Paxil® - Until further information is available, PAXIL® (paroxetine hydrochloride) should not be used in children and adolescents under 18 years of age - GlaxoSmithKlineJuly 10, 2003 · Health products